The FDA authorized marketing of software to assist medical professionals who examine body tissues in the detection of areas that are suspicious for cancer as an adjunct to the review of digitally-scanned slide images from prostate biopsies.
Prostate cancer specialists from the Radiotherapy Department at Norfolk and Norwich University Hospitals Foundation Trust have become the first in the world to use an innovative technique to help patients receiving treatment for prostate cancer. Some patients receiving radiotherapy for prostate cancer will have their treatment split into two portions. The first stage of killing the cancerous…
Researchers at Karolinska Institutet recently reported that magnetic resonance imaging (MRI) could reduce overdiagnoses and thereby improve prostate cancer screening. Now, the same research group has published a study in The Lancet Oncology, which shows that the addition of a novel blood test, the Stockholm3 test, can reduce the number of MRIs performed by a third while further preventing the…
Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher risk of the disease, including patients aged 50 years or older, without symptoms. In a paper published in the cancer journal Annals of Oncology, researchers report that the test accurately detected…
Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is.
Whole-body magnetic resonance imaging (WB-MRI) can detect prostate cancer and inform about treatment response and disease progression earlier and better than other imaging modalities. A Belgian expert will delve into the latest and future developments of the technique for prostate cancer and distant metastases imaging in a dedicated session at ECR. WB‐MRI and nuclear medicine -…
Hybrid PET/CT imaging can fully play to its strengths and steer treatment towards more effective procedures for diagnosing prostate cancer. The examination of the specific antigen PSMA with hybrid PET imaging enables treatment monitoring with significantly higher diagnostic accuracy than conventional imaging and therefore, Professor Clemens Cyran believes, will soon become the standard diagnostic…
Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer primarily based on PSA, a cancer factor in blood. However, as diagnostic accuracy is as low as 30%, a considerable number of patients undergo additional invasive biopsy and thus suffer from resultant side effects, such as bleeding and pain.
Our biological or circadian clock synchronizes all our bodily processes to the natural rhythms of light and dark. It’s no wonder then that disrupting the clock can wreak havoc on our body. In fact, studies have shown that when circadian rhythms are disturbed through sleep deprivation, jet lag, or shift work, there is an increased incidence of some cancers including prostate cancer, which is the…
Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have preliminarily validated an artificial intelligence (AI) tool to predict how likely the disease is to recur following surgical treatment for prostate cancer. The tool, called RadClip, uses AI algorithms to examine a variety of data, from MRI scans to molecular…
Men die about five years earlier than women across the world. As initiatives to boost awareness of men’s health unfolded in November, an international project is bringing the forefront of AI research to tackle prostate cancer (PC), the second most frequent type of cancer in men and the third most lethal in Europe.
Prostate cancer radiotherapy treatments guided by MRI are increasingly being explored to help improve patient outcomes and reduce toxicities after treatment. However, this development is being held back as the MRI approach is labour intensive and requires daily adaptive treatment planning, placing significant additional demands on clinician time and oncology services. To address this, a team of…
Pioneering research conducted by University of Virginia in collaboration with Manchester UK based APIS Assay Technologies Ltd has discovered Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase (HULLK) is detectable in non-invasive prostate cancer patient samples.
An up-and-coming gene therapy for blood disorders. A new class of medications for cystic fibrosis. Increased access to telemedicine. These are some of the innovations that will enhance healing and change healthcare in the coming year, according to a distinguished panel of clinicians and researchers from Cleveland Clinic. In conjunction with the 2020 Medical Innovation Summit, Cleveland Clinic…
If a father or brother has prostate cancer, his son or brother has an increased risk of this type of cancer. Whether this also applies when precancerous stages of this cancer are discovered in relatives has not yet been known. Now scientists have analyzed data from more than six million men to find out how high the risk of prostate cancer is in this case. Researchers at the German Cancer Research…
A new study sheds light on proteins in particles called extracellular vesicles, which are released by tumor cells into the bloodstream and promote the spread of cancer. The findings suggest how a blood test involving these vesicles might be used to diagnose cancer in the future, avoiding the need for invasive surgical biopsies.
A study of 4532 men in the Veneto region of Italy has found that those who were being treated for prostate cancer with androgen-deprivation therapies (ADT) were less likely to develop the coronavirus COVID-19.
Death rates from prostate cancer are predicted to fall in 2020 in the EU, largely due to better diagnosis and treatment, according to new research published in the leading cancer journal Annals of Oncology. In the latest predictions for cancer deaths in the EU for 2020, researchers led by Carlo La Vecchia (MD), Professor at the School of Medicine, University of Milan (Italy), show that since 2015…
Unnecessary prostate cancer biopsies could be reduced by 60 per cent thanks to new research from the University of East Anglia (UEA). Researchers have developed new methods to identify biomarkers for prostate cancer by combining information from multiple parts of urine samples. It is hoped that the breakthrough could help large numbers of men avoid an unnecessary initial biopsy.
Researchers at Karolinska Institutet have developed a method based on artificial intelligence for histopathological diagnosis and grading of prostate cancer. The AI-system has the potential to solve one of the bottlenecks in today’s prostate cancer histopathology by providing more accurate diagnosis and better treatment decisions. The study, presented in The Lancet Oncology, shows that the…
Prostate cancer is the second cause of cancer-related death in men. Currently, its diagnosis occurs via imaging and must be confirmed by biopsy. Simona Turco from the Eindhoven University of Technology (TU/e) wants to improve prostate cancer diagnosis by using machine learning algorithms to localize tumors and thereby replace entirely the necessity for biopsies. Besides, by combining this with…
Using MRI scans to target biopsies is more effective at detecting prostate cancers that are likely to need treatment than standard ultrasound guided biopsies alone, according to research published in JAMA Network Open. The research, led by the National Institute for Health Research (NIHR) and Universities of Bristol, Ottawa, Exeter and Oxford, combined the results from seven studies covering…
A new study has begun to test whether broccoli and garlic can help improve prostate health. The Norfolk Accumulation of Dietary Bioactives and Prostate Cancer (ADaPt) study has been launched by researchers at Quadram Institute Bioscience (QIB) and the Norfolk and Norwich University Hospital (NNUH). The study, which will take place at the NNUH-run Clinical Research Facility at the Quadram…
Prostate-specific membrane antigen imaging should be the positron emission tomography imaging agent of choice for men who have a prostate cancer recurrence after radical prostatectomy, which needs to be detected and located. For these men, it should become the standard of care, new research shows.
Image analysis of prostate cancer is a challenging area for clinicians. The disease shows a low mutation burden compared to melanoma and stomach cancer, for example, making morpho-molecular correlation more difficult, and there is often very low inflammation. With the role of tumour infiltrating lymphocytes in prostate cancer currently unclear – and with the advent of new approaches to prostate…